Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 51
- Registration Number
- NCT06945276
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT06942936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Khyber Teaching Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT06922344
- Locations
- 🇵🇰
Khyber Teaching Hospital, Peshawar, KPK, Pakistan
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06919991
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06906809
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06809608
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- Conditions
- RSV InfectionDrug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06847464
- Locations
- 🇺🇸
ICON, plc, San Antonio, Texas, United States
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06846528
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: ZE50-0134 or placebo
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT06787131
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Randwick NSW, Australia
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
- Conditions
- Barrett EsophagusClinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage I Esophageal Adenocarcinoma AJCC v8Esophageal Adenocarcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Endoscopic ProcedureDrug: Placebo AdministrationOther: Questionnaire AdministrationProcedure: Radiofrequency Ablation
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT06732388
- Locations
- 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.